Frontiers in gastroenterology (Lausanne, Switzerland)
Cure8 research brief
Why This Matters
The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s disease.
Who Should Pay Attention
Clinicians, researchers, and patients on biologic therapy (infliximab or ustekinumab) interested in biomarkers and noninvasive monitoring
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
Researchers profiled blood metabolites from 81 people with Crohn’s disease on biologic therapy (45 on infliximab, 36 on ustekinumab) and 45 healthy controls using targeted liquid chromatography–mass spectrometry. Even among patients in clinical remission, inflammatory markers (CRP and ESR) remained higher than in controls.
The study reports that infliximab-treated patients showed changes mainly in amino-acid metabolism (including l-arginine, l-glutamine, l-lysine) and energy pathways, while ustekinumab-treated patients showed changes in glutathione and purine metabolism (including adenosine and hypoxanthine).
The authors propose two diagnostic biomarker sets: one for the infliximab group (l-arginine, l-glutamine, l-lysine) and one for the ustekinumab group (glutathione, adenosine).
Keep In Mind
Structured content depth: abstract — this curation is grounded in the article abstract provided by the journal; findings are candidate biomarkers that require further validation before clinical use.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in gastroenterology (Lausanne, Switzerland)
AuthorsLin T, Hu X, Yuan K +7 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 23, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The ImproveCareNow Registry: Prediction of remission rates in paediatric Crohn's disease.
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
Immunomodulators and advanced therapies for maintenance of remission in Crohn's disease: systematic review and network meta-analysis.
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...